Overview

Study of GSK961081 in Healthy Volunteer Subjects

Status:
Completed

Trial end date:
2006-10-04

Target enrollment:

Participant gender:

Summary

GSK961081 is a new long-acting bronchodilator being developed for the treatment of chronic obstructive pulmonary disease (COPD). This study is the first clinical study in humans. The purpose of this study is to determine the safety, tolerability, pharmacokinetics and pharmacodynamics of GSK961081 in healthy male subjects.

Phase:

Phase 1

Details

Lead Sponsor:

GlaxoSmithKline
Theravance Biopharma

Collaborator:

GlaxoSmithKline